The Chemours Company (NYSE:CC) is Vision One Management Partners LP's 3rd Largest Position

Vision One Management Partners LP raised its stake in shares of The Chemours Company (NYSE:CC - Free Report) by 12.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,558,498 shares of the specialty chemicals company's stock after purchasing an additional 168,148 shares during the period. Chemours accounts for about 14.1% of Vision One Management Partners LP's portfolio, making the stock its 3rd biggest position. Vision One Management Partners LP owned about 1.04% of Chemours worth $26,339,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in CC. Quadrant Capital Group LLC grew its stake in shares of Chemours by 100.4% during the fourth quarter. Quadrant Capital Group LLC now owns 2,234 shares of the specialty chemicals company's stock valued at $38,000 after buying an additional 1,119 shares during the last quarter. Aster Capital Management DIFC Ltd bought a new position in shares of Chemours during the fourth quarter valued at approximately $48,000. Itau Unibanco Holding S.A. grew its stake in shares of Chemours by 39.3% during the fourth quarter. Itau Unibanco Holding S.A. now owns 3,554 shares of the specialty chemicals company's stock valued at $60,000 after buying an additional 1,003 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Chemours during the fourth quarter valued at approximately $91,000. Finally, KBC Group NV grew its stake in shares of Chemours by 38.2% during the fourth quarter. KBC Group NV now owns 6,176 shares of the specialty chemicals company's stock valued at $104,000 after buying an additional 1,708 shares during the last quarter. 76.26% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have commented on CC shares. The Goldman Sachs Group reduced their price objective on Chemours from $21.00 to $14.00 and set a "neutral" rating on the stock in a report on Wednesday, May 14th. Morgan Stanley reduced their price objective on Chemours from $22.00 to $15.00 and set an "equal weight" rating on the stock in a report on Monday, May 12th. Royal Bank of Canada reduced their price objective on Chemours from $17.00 to $14.00 and set an "outperform" rating on the stock in a report on Thursday, May 8th. Wall Street Zen downgraded Chemours from a "hold" rating to a "sell" rating in a report on Wednesday. Finally, Truist Financial reduced their price objective on Chemours from $27.00 to $22.00 and set a "buy" rating on the stock in a report on Monday, April 14th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat, Chemours has a consensus rating of "Hold" and a consensus target price of $17.56.

Insider Buying and Selling at Chemours

In related news, CFO Shane Hostetter acquired 4,450 shares of Chemours stock in a transaction on Monday, May 19th. The stock was acquired at an average price of $11.28 per share, for a total transaction of $50,196.00. Following the purchase, the chief financial officer now owns 59,694 shares of the company's stock, valued at approximately $673,348.32. This represents a 8.06% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.47% of the company's stock.

Chemours Stock Down 5.1%

Shares of Chemours stock traded down $0.56 during trading on Friday, reaching $10.30. The company's stock had a trading volume of 2,992,136 shares, compared to its average volume of 2,088,641. The company has a quick ratio of 0.92, a current ratio of 1.68 and a debt-to-equity ratio of 6.70. The company has a market cap of $1.54 billion, a price-to-earnings ratio of 18.06 and a beta of 1.76. The Chemours Company has a 1-year low of $9.33 and a 1-year high of $27.25. The company has a 50-day simple moving average of $11.97 and a two-hundred day simple moving average of $16.02.

Chemours (NYSE:CC - Get Free Report) last issued its earnings results on Tuesday, May 6th. The specialty chemicals company reported $0.13 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.19 by ($0.06). The firm had revenue of $1.37 billion during the quarter, compared to analysts' expectations of $1.36 billion. Chemours had a return on equity of 26.54% and a net margin of 1.51%. The business's revenue was up .4% on a year-over-year basis. During the same quarter last year, the business earned $0.32 EPS. As a group, equities analysts forecast that The Chemours Company will post 2.03 earnings per share for the current year.

Chemours Dividend Announcement

The company also recently announced a dividend, which will be paid on Monday, June 16th. Investors of record on Monday, May 19th will be paid a $0.0875 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a yield of 3.17%. Chemours's dividend payout ratio (DPR) is 175.00%.

Chemours Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.